HIV cocktail aims to free patients from daily pills

NCT ID NCT06805656

Recruiting now Disease control Sponsor: Federal University of São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether a mix of intensified antiretrovirals, a latency-reversing drug, an anti-proliferative drug, and a personalized vaccine can shrink the hidden HIV reservoir enough to allow people to stop their daily medication. The study will enroll 70 adults with well-controlled HIV. Researchers will monitor viral rebound and immune responses during a treatment interruption.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Maraviroc, Dolutegravir, Auranofin, Nicotinamide, and a personalized dendritic cell vaccine
What this could lead to: If successful, this could point toward a way for people with HIV to stay healthy without needing daily antiretroviral pills.
What could go wrong: This is a small, early-phase trial (70 people) and previous attempts at HIV remission have failed. The combination approach is complex and may not work for everyone, or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV I INFECTION

Contacts and locations

Locations

CCDI
RECRUITING

São Paulo, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.